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were identiﬁed, with both groups evenly matched at baseline. The incidence of in-
hospital mortality was 70% in the reinsertion group and 31.2% in the controls (OR
2.2; p¼0.005). The composite secondary endpoint of death, LVAD insertion during
index hospitalization or discharge to hospice was also signiﬁcantly higher in the
reinsertion group than the controls (85% vs 42.1%; OR¼2.0; p¼0.002). We also
performed multivariate analysis and found that use of multiple IABPs was indepen-
dently predictive of in-hospital mortality (p<0.05).
Conclusion: Reinsertion of IABP after failure of initial wean is associated with
extremely high in-hospital mortality and independently predicts mortality in patients
with cardiogenic shock. This study supports the notion that if IABP weaning or
removal is unsuccessful, alternative and more aggressive regimens of short or even
long-term mechanical support be considered where appropriate such as surgical
LVAD or extra-corporeal membrane oxygenation (ECMO).VALVE & STRUCTURAL HEART
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Should a New Bleeding Risk Score be Developed to Account for the Added Risks in
Patients With Moderate or Severe Aortic Stenosis Who Undergo Percutaneous
Coronary Intervention?
Christopher Huffman, Rebecca Torguson, Fang Chen, Augusto Pichard, Lowell Satler,
Kenneth Kent, William Suddath, Ron Waksman
Medstar Washington Hospital Center, Washington, DC
Background: Aortic stenosis (AS) is associated with an increased risk of bleeding, but
little is known about the risk of bleeding during percutaneous coronary intervention
(PCI) in patients with AS. In the age of transcatheter aortic valve replacement
(TAVR), patients with AS frequently undergo PCI prior to TAVR; therefore, un-
derstanding whether these patients have a higher risk of bleeding is critical.
Methods: This retrospective study included 7,926 patients who underwent PCI from
March 18, 2004 to January 31, 2013. Patients were categorized according to the
presence of hemodynamically signiﬁcant AS: Moderate/Severe AS (n¼354) and Mild/
No AS (n¼7,572). The National Cardiovascular Data Registry (NCDR) deﬁnition of
a bleeding event (requiring transfusion, prolonged hospital stay, or drop in hemoglobin
>3.0 mg/dL) was used as the primary outcome, and the NCDR PCI Bleeding Risk
Score (risk score components in Table) was used to control for the underlying bleeding
risk due to baseline patient characteristics.
Results: Logistic regression showed that the NCDR PCI Bleeding Risk Score did
predict bleeding outcomes in these patients. Patients with AS had signiﬁcantly higher
NCDR PCI Bleeding Risk Scores as well as higher rates of bleeding events (Table).
There was not, however, an independent association between AS and bleeding out-
comes. The addition of AS to the risk score using Net Reclassiﬁcation Improvement
did not enhance the model’s ability to predict bleeding (p¼0.71).Moderate/Severe
ASMild/No
AS p ValueAge, years 79.9 10.98 65.06 12.23 < 0.001Female Gender, % 45.5 35.9 < 0.001Congestive Heart Failure, % 37.9 16.7 < 0.001Congestive Heart Failure Class III or
IV, %20.7 8.4 < 0.001History of PCI, % 27.5 30.6 0.212History of Peripheral Vascular
Disease, %27.9 16.1 < 0.001Chronic Renal Insufﬁciency, % 37.7 18.0 < 0.001Myocardial Infarction This
Admission, %27.8 38.1 < 0.001Cardiogenic Shock, % 2.1 3.5 0.158NCDR PCI Bleeding Score 18.71 7.55 12.97 7.56 < 0.001Hematocrit Drop > 15, % 4.1 2.1 0.011Hematoma, % 5.8 2.2 < 0.001NCDR Bleeding Event, % 10.3 4.9 < 0.001Conclusions: These data suggest that the NCDR PCI Bleeding Risk Score appro-
priately adjusts for bleeding risks in patients with moderate or severe AS. As more
patients with increasingly severe comorbidities undergo TAVR evaluation, with some
requiring PCI, this risk score may need further adjustment to account for the
increasingly complex and frail nature of the TAVR population.
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A Comparison of Post Implant Aortic Valve Gradient of Transcatheter and Surgical
Tissue Valves in Symptomatic Severe Aortic Stenosis
Mohammed Salem, Kamran Baig, Robert Henderson, Thomas Mathew
Nottingham University Hospitals, Nottingham, United Kingdom
Background: The design and ﬂow proﬁle of transcatheter aortic valve (TAVI) is
different from surgical prosthetic valve. We compared the post implantation echo-
cardiographic aortic valve gradient of patients undergoing TAVI using Edwards
Sapien in our institution to that of surgically implanted bioprosthetic valves (SAVR)
using St Jude Epic, Hancock and Mitrﬂow valves during the same period.
Methods: Consecutive patients who underwent TAVI between January 2010 and
May 2011 were included. Patients who underwent SAVR for native aortic stenosis
(AS) were identiﬁed from our database and patients who completed at least one follow
up transthoracic echocardiogram (TTE) were included for ﬁnal analysis. The last
performed TTE was included for analysis in both groups.
Results: Thirty six patients underwent TAVI valves between January 2010 and May
2011 and TTE data were available for 34 patients who were included for ﬁnal analysis.
Seventy two patients underwent SAVR with a bioprosthetic valve during the same
period and TTE data were available for 30 patients who were included for ﬁnal
analysis. Mean age (TAVI 83.4  5.8 vs SAVR 76.3  5.2 years, p <0.001) and
logistic Euroscore (TAVI 26.4  12.5 vs SAVR 8.4  5.2, p <0.001) were signiﬁ-
cantly higher in the TAVI group but the body surface area an important determinant
of echo gradient was similar in both groups (TAVI 1.8  0.23 vs SAVR 1.83  0.24,
p¼0.34). The pre procedure peak aortic valve gradients (TAVI 85.2  20.1 vs SAVR
83.0  22.3, p¼0.67) were similar in both groups but the mean aortic valve gradients
(TAVI 53.2  14.46 vs SAVR 45.8  12.8, p <0.05) were signiﬁcantly higher in
the TAVI group. The post implant peak gradients (TAVI 21.09  11.5 vs SAVR
30.24  10.6, p <0.005) and mean gradients (TAVI 12.66  7.9 vs SAVR
